Related Experiment Video

Updated: Jul 14, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K

Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus

Bruno Rocha de Macedo1, Carla Solórzano1, Angela Hyder-Wright2,3

  • 1Department of Paediatrics, University of Oxford, Oxford, UK.

BMJ Open
|November 25, 2025
PubMed

Insights

This study investigates if VAXNEUVANCE (PCV15) reduces Streptococcus pneumoniae serotype 3 (SPN3) carriage in adults. The controlled human infection model assesses SPN3 acquisition, density, and duration post-vaccination.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Streptococcus pneumoniae serotype 3 (SPN3) causes significant invasive pneumococcal disease globally.
  • Current vaccines offer limited protection against SPN3, necessitating improved vaccine strategies.
  • A controlled human infection model provides a robust platform to evaluate vaccine efficacy against specific pneumococcal serotypes.

Purpose of the Study:

  • To assess the impact of VAXNEUVANCE (15-valent pneumococcal conjugated vaccine, PCV15) on SPN3 carriage acquisition, density, and duration.
  • To compare immune responses elicited by PCV15 versus placebo in healthy adults.
  • To explore gene expression changes in nasal tissue following PCV15 vaccination.

Main Methods:

  • A double-blind, randomized controlled trial involving healthy adults aged 18-50 years.
  • Participants receive either PCV15 or placebo, followed by intranasal inoculation with SPN3 one month later.
  • Monitoring includes safety, SPN3 colonization status, density, duration, and immune responses over 28 days. Exploratory nasal biopsies will assess gene expression.

Main Results:

  • Primary endpoint: Rate of SPN3 acquisition in PCV15 recipients versus placebo.
  • Secondary endpoints: Density and duration of SPN3 colonization, comparative immune responses.
  • Exploratory analysis: Gene expression changes in nasal tissue post-PCV15 vaccination.

Conclusions:

  • The study will determine if PCV15 can effectively reduce SPN3 carriage.
  • Findings will inform the development of next-generation pneumococcal vaccines.
  • Understanding the impact on carriage may lead to reduced disease burden.
Abstract

Keywords:
ImmunologyRespiratory infectionsVaccination

More Related Videos

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

13.0K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.0K

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...